CancerDrs

Cervical Cancer clinical trials

300 actively recruiting cervical cancer trials in the United States. Largely HPV-driven. Trials span prevention, early-stage (often curable with surgery + radiation), and advanced/metastatic disease.

Data from ClinicalTrials.gov · last refreshed · Cervical Cancer stats on SEER

54
Phase 1
111
Phase 2
12
Phase 3
3
Phase 4
120
Other

Cervical Cancer by the numbers (U.S.)

13,360
Estimated new cases (2025)
4,320
Estimated deaths (2025)
68%
5-year relative survival
50
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse cervical cancer trials by state

Top trials by phase + site coverage

Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Locations:
  • Site 160 — Mobile, Alabama
  • Site 102 — Prescott, Arizona
  • Site 125 — Scottsdale, Arizona

+ 57 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Locations:
  • Ironwood Cancer and Research Center — Chandler, Arizona
  • Providence St Jude Medical Center — Fullerton, California
  • Valkyrie Clinical Trials — Los Angeles, California

+ 35 more sites in the U.S.

Phase 3 Recruiting Industry

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 p…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06459180
Locations:
  • USA Mitchell Cancer Institute-Clinical Trials ( Site 4126) — Mobile, Alabama
  • Providence Alaska Medical Center ( Site 4137) — Anchorage, Alaska
  • HonorHealth (HH) ( Site 8002) — Phoenix, Arizona

+ 35 more sites in the U.S.

Phase 3 Recruiting Industry

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…

Sponsor: AstraZeneca
NCT ID: NCT06079671
Locations:
  • Research Site — Birmingham, Alabama
  • Research Site — Phoenix, Arizona
  • Research Site — Tucson, Arizona

+ 25 more sites in the U.S.

Phase 3 Recruiting Industry

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • City of Hope — Duarte, California
  • University of California at San Diego Moores Cancer Center — La Jolla, California

+ 23 more sites in the U.S.

Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Locations:
  • City of Hope Corona — Corona, California
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • City of Hope at Irvine Lennar — Irvine, California

+ 23 more sites in the U.S.

Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Locations:
  • Mount Sinai Comprehensive Cancer Center ( Site 6000) — Miami Beach, Florida
  • Florida Cancer Specialists - East ( Site 7000) — West Palm Beach, Florida
  • TRIALS 365 ( Site 6008) — Shreveport, Louisiana

+ 10 more sites in the U.S.

Phase 3 Recruiting Industry

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…

Sponsor: SOFIE
NCT ID: NCT07217704
Locations:
  • Helios CR Inc./RadNet — Cerritos, California
  • Hoag Memorial Hospital — Irvine, California
  • UCLA — Los Angeles, California

+ 7 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn ab…

Sponsor: Rakuten Medical, Inc.
NCT ID: NCT06699212
Locations:
  • City of Hope — Duarte, California
  • University of Miami — Miami, Florida
  • Tampa General Hospital — Tampa, Florida

+ 5 more sites in the U.S.

Phase 3 Recruiting Academic/Other

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…

Sponsor: Mayo Clinic
NCT ID: NCT06915727
Locations:
  • Mayo Clinic in Rochester — Rochester, Minnesota
Phase 2, Phase 3 Recruiting Academic/Other

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of…

Sponsor: Andrei Iagaru
NCT ID: NCT05891769
Locations:
  • Stanford Hospital and Clinics — Stanford, California
Phase 3 Recruiting Academic/Other

Head and Neck Cancer Study Project in the Geriatric Population

This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as …

Sponsor: Brown University
NCT ID: NCT06998069
Locations:
  • Rhode Island and The Miriam Hospitals — Providence, Rhode Island

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25